BioMarin Pharmaceuticals BMRN EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's EPS (diluted)?
- BioMarin Pharmaceuticals (BMRN) reported EPS (diluted) of $0.54 in Q1 2026.
- How has BioMarin Pharmaceuticals's EPS (diluted) changed year-over-year?
- BioMarin Pharmaceuticals's EPS (diluted) decreased by 43.2% year-over-year, from $0.95 to $0.54.
- What is the long-term trend for BioMarin Pharmaceuticals's EPS (diluted)?
- Over 3 years (2021 to 2024), BioMarin Pharmaceuticals's EPS (diluted) has grown at a 83.1% compound annual growth rate (CAGR), from -$0.36 to $2.21.
- What does EPS (diluted) mean?
- The profit per share assuming all potential shares that could be created are issued.
- How do you interpret EPS (diluted)?
- A higher value indicates strong earnings even when accounting for potential dilution, signaling robust profitability.
- How does EPS (diluted) compare across companies?
- Standardized metric used by analysts to assess the true earnings potential per share for existing investors.